Literature DB >> 31637196

Association of urinary albumin excretion with central foveal thickness and intravitreal conbercept treatment frequency in patients with diabetic macular edema.

Zi-Yao Liu1, Xiao-Jie Ma2, Ding-Ying Liao1, Xin-Di Liu3, Ling Bai1, Jing Yao1, Min Xu4, Yu-Ping Zheng1.   

Abstract

AIM: To investigate the effect of albuminuria on diabetic macular edema (DME) and the possible association between baseline urinary albumin excretion (UAE) and intravitreal conbercept (IVC) treatment frequency in DME patients.
METHODS: In this hospital-based retrospective study, a total of 350 in-patients with type 2 diabetes mellitus were recruited and their clinical records were reviewed. Thereafter, 52 patients identified with severe non-proliferative diabetic retinopathy (NPDR) combined with albuminuria were divided into the microalbuminuria (UAE 30-300 mg/24h) and macroalbuminuria (UAE>300 mg/24h) groups, which were compared and analyzed by both independent sample t-test and Chi-square test. Correlations between the systemic variables and the central foveal thickness (CFT) were evaluated using Spearman's correlation and linear regression analyses. Of the 52 patients with center-involved DME, 43 received an initial combined injection of conbercept (0.5 mg/0.05 mL) and triamcinolone acetonide (1 mg/0.05 mL), followed by an IVC injection, as needed. The relationship between baseline UAE and number of IVC injections during the first year of treatment was analyzed using Spearman's partial correlation.
RESULTS: Of 350 patients, a higher incidence of DME was observed in severe non-proliferative retinopathy (NPDR) patients than that observed in other groups. By dividing the 52 patients with severe NPDR into the micro- and macro-albuminuria subgroups, significant differences in CFT, systolic blood pressure, total cholesterol and serum creatinine levels, and UAE were revealed. Furthermore, a positive liner correlation between the UAE and CFT was found. Finally, the partial correlation coefficient adjusted for either the CFT or UAE indicated that both parameters directly correlated with the number of IVC injections administered during the 12mo of follow-up.
CONCLUSION: Generally, macular edema occurred in patients with severe NPDR, for whom the UAE is an independent risk predictor of DME. The baseline UAE and CFT predicted the treatment frequency of IVC injections administered in the first year for eyes with DME. International Journal of Ophthalmology Press.

Entities:  

Keywords:  diabetic macular edema; intravitreal conbercept injection; treatment frequency; urinary albumin excretion

Year:  2019        PMID: 31637196      PMCID: PMC6796094          DOI: 10.18240/ijo.2019.10.12

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  33 in total

1.  The North Jutland County Diabetic Retinopathy Study (NCDRS) 2. Non-ophthalmic parameters and clinically significant macular oedema.

Authors:  L L Knudsen; H-H Lervang; S Lundbye-Christensen; A Gorst-Rasmussen
Journal:  Br J Ophthalmol       Date:  2007-01-03       Impact factor: 4.638

2.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

3.  Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy.

Authors:  Søren T Knudsen; Toke Bek; Per L Poulsen; Marianne N Hove; Michael Rehling; Carl E Mogensen
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

4.  Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients.

Authors:  Jee Taek Kim; Dong Hoon Lee; Soo Geun Joe; June-Gone Kim; Young Hee Yoon
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-09       Impact factor: 4.799

5.  The Association of Estimated Glomerular Filtration Rate With Diabetic Retinopathy and Macular Edema.

Authors:  Ryan Eyn Kidd Man; Muhammad Bayu Sasongko; Jie Jin Wang; Richard MacIsaac; Tien Yin Wong; Charumathi Sabanayagam; Ecosse L Lamoureux
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-07       Impact factor: 4.799

Review 6.  Identifying risk factors for clinically significant diabetic macula edema in patients with type 2 diabetes mellitus.

Authors:  Kyuzi Kamoi; Keiji Takeda; Kaoru Hashimoto; Reiko Tanaka; Shinya Okuyama
Journal:  Curr Diabetes Rev       Date:  2013-05

7.  Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema.

Authors:  Meng-Ju Tsai; Yi-Ting Hsieh; Elizabeth P Shen; Yi-Jie Peng
Journal:  J Ophthalmol       Date:  2017-07-27       Impact factor: 1.909

8.  Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema.

Authors:  Yuki Mori; Tomoaki Murakami; Kiyoshi Suzuma; Kenji Ishihara; Shin Yoshitake; Masahiro Fujimoto; Yoko Dodo; Tatsuya Yoshitake; Yuko Miwa; Akitaka Tsujikawa
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

9.  Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11).

Authors:  Merlin C Thomas; Richard J Macisaac; George Jerums; Andrew Weekes; John Moran; Jonathan E Shaw; Robert C Atkins
Journal:  Diabetes Care       Date:  2009-05-26       Impact factor: 19.112

10.  Diabetic Retinopathy in Patients with Diabetic Nephropathy: Development and Progression.

Authors:  Chi-Juei Jeng; Yi-Ting Hsieh; Chung-May Yang; Chang-Hao Yang; Cheng-Li Lin; I-Jong Wang
Journal:  PLoS One       Date:  2016-08-26       Impact factor: 3.240

View more
  4 in total

1.  Nomogram-based prediction of clinically significant macular edema in diabetes mellitus patients.

Authors:  Zijing Li; Xiaowen Deng; Lijun Zhou; Tu Lu; Yuqing Lan; Chenjin Jin
Journal:  Acta Diabetol       Date:  2022-06-24       Impact factor: 4.087

2.  Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema.

Authors:  Ivan Pochou Lai; Wei-Lun Huang; Chung-May Yang; Chang-Hao Yang; Tzyy-Chang Ho; Yi-Ting Hsieh
Journal:  J Diabetes Res       Date:  2020-08-18       Impact factor: 4.011

3.  Impact of systemic parameters before commencing anti-vascular endothelial growth factor therapy for diabetic macular edema - Pan-Indian survey of retina specialists.

Authors:  P Mahesh Shanmugam; Payal Shah; Rajesh Ramanjulu; Divyansh Mishra
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

4.  Association of periodontitis and diabetic macular edema in various stages of diabetic retinopathy.

Authors:  Marlene Lindner; Behrouz Arefnia; Domagoj Ivastinovic; Harald Sourij; Ewald Lindner; Gernot Wimmer
Journal:  Clin Oral Investig       Date:  2021-06-22       Impact factor: 3.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.